Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.57 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277792 | 1.00 | PDE4B (0.57) | PDE4BTACR1RORCUSP30PPARG | |
| SCHEMBL10277788 | 1.00 | PDE4B (0.57) | PDE4BTACR1RORCUSP30PPARG | |
| SCHEMBL10182023 | 0.90 | TACR1 (0.52) | PDE4BTACR1RORCUSP30 | |
| SCHEMBL10277512 | 0.89 | PDE4B (0.68) | PDE4BTACR1RORCUSP30SLC6A4 | |
| SCHEMBL326647 | 0.89 | PDE4B (0.68) | PDE4BTACR1RORCUSP30SLC6A4 | |
| SCHEMBL10069997 | 0.87 | USP30 (0.50) | PDE4BTACR1RORCUSP30 | |
| SCHEMBL23021431 | 0.86 | RORC (0.62) | PDE4BTACR1RORCUSP30 | |
| SCHEMBL1254775 | 0.86 | RORC (0.62) | PDE4BTACR1RORCUSP30 | |
| SCHEMBL2738527 | 0.86 | RORC (0.62) | PDE4BTACR1RORCUSP30 | |
| SCHEMBL1254778 | 0.86 | RORC (0.62) | PDE4BTACR1RORCUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | PDE4B 261/4885TACR1 2419/4885RORC 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.